Clinical Trial Update: Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors [Phase 3]

View source ↗

Summary

Phase 3 trial comparing thalidomide to infliximab in new-onset Crohn's disease with poor prognostic factors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Infliximab (infliximab)
• Thalidomide (thalidomide)

Snippet

Sponsor: IRCCS Burlo Garofolo | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED